Pharm-Olam International Celebrates 20-Year Anniversary
HOUSTON, TEXAS - November 4th, 2014.
Pharm-Olam International Ltd., a multi-national, full-service CRO to biopharmaceutical and device industries is proud to celebrate 20 years of successfully helping our sponsors create a healthier world.
“We have remained focused on our mission to help clients expedite time to market and contributed to the approval of many new drugs and treatments,” said Dr. Zev Munk, Chairman of Pharm-Olam. “After experiencing record growth in the last three years, we are excited about our continued expansion of coverage in Asia, Latin America, and the Middle East. In the years to come we anticipate exponential growth across all our service offerings.”
Dr. Munk, who served as a clinical investigator on over 200 studies while managing a private practice in the United States, founded Pharm-Olam with Eugene Barg in 1994. Pharm-Olam started in Eastern Europe (1995), and gradually expanded into Western Europe (1999), North America (2003), India (2003), Latin America (2005), South Africa (2006), and the Middle East (2014). In 2006, Pharm-Olam began offering direct data management, biostatistics, and medical safety services to become a full-service CRO. Pharm-Olam currently has 29 offices worldwide and operates in over 40 countries.
The continuous delivery of quality and service has earned Pharm-Olam a reputation for expertise in an extensive range of clinical trial therapeutic areas and phases. Pharm-Olam is proud to have a diverse client base that includes pharmaceutical, biotech and device companies of all sizes.
“We sincerely appreciate the support of our customers and partners over the years. We are also very proud of the professionalism and dedication of our staff worldwide who have shared our positive attitude and development goals with our sponsors", affirmed Dr. Munk.
About Pharm-Olam International
Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.